interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Seladelpar Lysine

Generic competition · all medicines · read 12 November 2026

Is there a generic of Seladelpar Lysine, and who makes it?

Seladelpar Lysine appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Seladelpar Lysine1 dosage-form group in the Orange Book
0generic makers listed
  1. Seladelpar Lysine appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Capsule, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Livdelzi. No generic is listed as marketed.

2020202520302035204001brand 2024data datePatent 7301050 listed to expire 2 August 2027Patent 7709682 listed to expire 13 September 2027Patent 11596614 listed to expire 19 March 2035Patent 11406611 listed to expire 19 March 2035Patent 9486428 listed to expire 19 March 2035Patent 10272058 listed to expire 13 March 2038Exclusivity NCE to 14 August 2029Exclusivity ODE-486 to 14 August 2031
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 14 August 2029Exclusivity NCE Livdelzi
  • 14 August 2031Exclusivity ODE-486 Livdelzi
  • 2 August 2027Patent 7301050 drug substance
  • 13 September 2027Patent 7709682 drug substance
  • 19 March 2035Patent 11596614
  • 19 March 2035Patent 11406611
  • 19 March 2035Patent 9486428
  • 13 March 2038Patent 10272058

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.